Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
HRTX Heron Therapeutics Inc
IFBD Infobird Co Ltd
JACK Jack in the Box Inc
MVLY Mission Valley Bancorp
CLSD Clearside Biomedical Inc
GBRGU Goldenbridge Acquisition Ltd
CHMI-B Cherry Hill Mortgage Investment Corp
KAIIU Kismet Acquisition Two Corp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.

Closing Price
$123.64
Day's Change
-0.68 (-0.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.01
Day's Low
121.25
Volume
(Light)
Volume:
3,942,637

10-day average volume:
5,723,584
3,942,637

MRNA's position in the Biotechnology industry

Industry PeersMRNAALNYBMRNSRPTIONS

Summary

Company ProfileModerna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA...
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and...
Go to ALNY summary
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and...
Go to BMRN summary
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted...
Go to SRPT summary
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its...
Go to IONS summary
52-Week Change

VS. INDUSTRY
-72.80%
7.40%
6.99%
19.49%
16.21%
Market Cap

VS. INDUSTRY
$48.4B
$24.1B
$15.7B
$9.5B
$6.1B
Beta

VS. INDUSTRY
1.7
0.6
0.3
1.2
0.6
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
3.77x
--
366.54x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$23.0B
$884.2M
$1.9B
$835.2M
$848.8M
Profit Margin

VS. INDUSTRY
61.12%
-110.91%
2.62%
-60.66%
-3.32%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
227.58%
28.61%
-0.26%
39.18%
23.42%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.